Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) – Equities researchers at Leerink Swann issued their FY2022 earnings per share estimates for Pacira Pharmaceuticals in a research note issued on Tuesday. Leerink Swann analyst A. Fadia forecasts that the company will post earnings per share of $2.40 for the year. Leerink Swann currently has a “Market Perform” rating and a $46.00 price target on the stock.

A number of other brokerages have also recently weighed in on PCRX. Mizuho cut shares of Pacira Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $53.00 to $44.00 in a report on Wednesday, November 29th. Royal Bank of Canada set a $54.00 target price on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday. Canaccord Genuity set a $46.00 price objective on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Thursday. Finally, HC Wainwright set a $55.00 price objective on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $49.00.

Shares of Pacira Pharmaceuticals (PCRX) traded down $0.45 during trading hours on Friday, reaching $42.45. 752,735 shares of the company were exchanged, compared to its average volume of 1,132,725. The company has a market capitalization of $1,720.00, a PE ratio of -32.40 and a beta of 2.20. Pacira Pharmaceuticals has a 1 year low of $29.81 and a 1 year high of $58.95. The company has a quick ratio of 6.24, a current ratio of 6.99 and a debt-to-equity ratio of 1.03.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.15. The firm had revenue of $67.30 million during the quarter, compared to analysts’ expectations of $68.99 million. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period last year, the firm posted $0.20 earnings per share.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in Pacira Pharmaceuticals by 9.2% in the 2nd quarter. BlackRock Inc. now owns 3,478,281 shares of the company’s stock worth $165,914,000 after acquiring an additional 294,494 shares during the period. Vanguard Group Inc. raised its holdings in Pacira Pharmaceuticals by 7.4% in the 2nd quarter. Vanguard Group Inc. now owns 3,072,074 shares of the company’s stock worth $146,538,000 after acquiring an additional 211,982 shares during the period. HealthCor Management L.P. raised its holdings in Pacira Pharmaceuticals by 63.1% in the 2nd quarter. HealthCor Management L.P. now owns 1,793,799 shares of the company’s stock worth $85,564,000 after acquiring an additional 693,799 shares during the period. Westfield Capital Management Co. LP raised its holdings in Pacira Pharmaceuticals by 5.3% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,285,850 shares of the company’s stock worth $48,284,000 after acquiring an additional 64,510 shares during the period. Finally, Macquarie Group Ltd. raised its holdings in Pacira Pharmaceuticals by 5.8% in the 3rd quarter. Macquarie Group Ltd. now owns 1,154,545 shares of the company’s stock worth $43,353,000 after acquiring an additional 63,015 shares during the period.

In other news, SVP James B. Jones sold 850 shares of the firm’s stock in a transaction on Monday, November 20th. The shares were sold at an average price of $41.11, for a total transaction of $34,943.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO David M. Stack sold 58,885 shares of the firm’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $38.34, for a total transaction of $2,257,650.90. Following the transaction, the chief executive officer now owns 159,164 shares in the company, valued at approximately $6,102,347.76. The disclosure for this sale can be found here. Insiders have sold a total of 70,075 shares of company stock worth $2,707,452 in the last 90 days. 6.60% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: “Leerink Swann Comments on Pacira Pharmaceuticals, Inc.’s FY2022 Earnings (PCRX)” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/01/05/leerink-swann-comments-on-pacira-pharmaceuticals-inc-s-fy2022-earnings-pcrx.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Earnings History and Estimates for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.